OTC Markets OTCPK - Delayed Quote USD

Bayer Aktiengesellschaft (BAYRY)

Compare
7.72 -0.01 (-0.13%)
At close: August 30 at 4:00 PM EDT
Loading Chart for BAYRY
DELL
  • Previous Close 7.73
  • Open 7.73
  • Bid 7.71 x 36200
  • Ask 7.72 x 40000
  • Day's Range 7.69 - 7.74
  • 52 Week Range 6.82 - 13.82
  • Volume 38,395
  • Avg. Volume 945,228
  • Market Cap (intraday) 30.337B
  • Beta (5Y Monthly) 0.92
  • PE Ratio (TTM) --
  • EPS (TTM) -0.36
  • Earnings Date Nov 12, 2024
  • Forward Dividend & Yield 0.03 (0.38%)
  • Ex-Dividend Date Apr 29, 2024
  • 1y Target Est 21.79

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

www.bayer.com

96,567

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BAYRY

View More

Research Reports: BAYRY

View More

Performance Overview: BAYRY

Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BAYRY
16.02%
DAX PERFORMANCE-INDEX
12.87%

1-Year Return

BAYRY
43.87%
DAX PERFORMANCE-INDEX
18.68%

3-Year Return

BAYRY
39.95%
DAX PERFORMANCE-INDEX
19.27%

5-Year Return

BAYRY
51.66%
DAX PERFORMANCE-INDEX
59.70%

Compare To: BAYRY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAYRY

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    30.33B

  • Enterprise Value

    66.11B

  • Trailing P/E

    --

  • Forward P/E

    5.35

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.58

  • Price/Book (mrq)

    0.76

  • Enterprise Value/Revenue

    1.27

  • Enterprise Value/EBITDA

    6.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -2.69%

  • Return on Assets (ttm)

    3.71%

  • Return on Equity (ttm)

    -3.45%

  • Revenue (ttm)

    47.11B

  • Net Income Avi to Common (ttm)

    -1.27B

  • Diluted EPS (ttm)

    -0.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.02B

  • Total Debt/Equity (mrq)

    129.94%

  • Levered Free Cash Flow (ttm)

    6.26B

Research Analysis: BAYRY

View More

Company Insights: BAYRY

People Also Watch